{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:05Z","timestamp":1787020745887,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hereditary angioedema (HAE) is a rare monogenic disease, and there are few reports on its clinical characteristics, particularly its drug efficacy, in China. The objective of this study was to gain insight into the clinical characteristics of HAE in Chinese patients, and the efficacy and safety of prophylactic treatment with lanadelumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort included 22 patients with a median age of 35.0 years (IQR: 27.0\u201348.3 years). The male-to-female ratio was 1:1.75. The median age at onset was 15.5 years (IQR: 10.0\u201321.3 years), with a median diagnostic delay of 18.5 years. A significant positive correlation was found between patient age and the duration of diagnostic delay (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.750;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.000). In the cohort, 18 patients (81.8%) had Type I HAE, whereas 4 patients (18.2%) had Type II HAE. The average monthly frequency of attacks was 1.0 (IQR: 0.3, 1.3). Ten patients (45.5%) experienced onset following minor trauma\/local bumps\/pressure\/heat exposure, which was the most common precipitating factor; 7 patients (31.8%) experienced spontaneous onset without apparent precipitating factors. A family history was reported for 16 patients (72.7%). Six patients (27.3%) had concomitant diseases involving various positive autoantibodies or confirmed autoimmune diseases. Eleven patients (50.0%) in this cohort were either currently receiving or had previously received lanadelumab treatment, with a median treatment duration of 7 months (IQR: 3\u201310 months). Nine patients reached the steady-state period of treatment (&gt;\u200970 days). Eight patients experienced no oedema attack during treatment. There was a significant reduction in the frequency of attacks and a significant improvement in quality of life by Day 30 (D30) posttreatment, with a decrease of 91.5% in the average monthly frequency of attacks. The average monthly frequency of attacks decreased by 94.6% and 96.2% after 3 months of treatment and at the time of the last injection, respectively, with no life-threatening laryngeal oedema attacks. Only 5 patients (45.5%) experienced local adverse reactions during treatment, and no severe adverse reactions were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>(1) The median age at onset, diagnostic delay, and precipitating factors in this cohort were consistent with previously reported data from domestic studies. However, the proportion of Type 2 patients was greater than that in prior domestic reports, and a trend towards earlier diagnosis in younger patients was observed; notably, this cohort identified a high proportion (27.3%) of patients with positive autoantibodies or confirmed autoimmune diseases for the first time in China. (2) After treatment with lanadelumab, patients experienced significant improvements in symptoms, quality of life, and anxiety\/depression levels. Symptom control was achieved by D30 prior to the drug steady state-period and was maintained throughout the entire treatment period. No serious adverse reactions were observed during the treatment, indicating a high safety profile for the medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry, ChiCTR2500098307, 2025\/03\/05.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03988-7","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T17:46:39Z","timestamp":1755539199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A single-centre retrospective study on the clinical characteristics of patients with hereditary angioedema and the therapeutic effect of lanadelumab"],"prefix":"10.1186","volume":"20","author":[{"given":"Yanhua","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinshi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"7","key":"3988_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","volume":"80","author":"HJ Longhurst","year":"2019","unstructured":"Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med. 2019;80(7):391\u20138. https:\/\/doi.org\/10.12968\/hmed.2019.80.7.391.","journal-title":"Br J Hosp Med"},{"issue":"5","key":"3988_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/all.12380","volume":"69","author":"M Cicardi","year":"2014","unstructured":"Cicardi M, Aberer,A W, Banerji,M Bas JA, Bernstein K, Bork, et al. Classification, diagnosis, andapproach to treatment for angioedema: consensus report from the hereditary angioedema international working group. Allergy. 2014;69(5):602\u201316. https:\/\/doi.org\/10.1111\/all.12380.","journal-title":"Allergy"},{"issue":"Suppl 1","key":"3988_CR3","doi-asserted-by":"publisher","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","volume":"41","author":"WR Lumry","year":"2020","unstructured":"Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease[J]. Allergy Asthma Proc. 2020;41(Suppl 1):S08\u201313. https:\/\/doi.org\/10.2500\/aap.2020.41.200050.","journal-title":"Allergy Asthma Proc"},{"key":"3988_CR4","doi-asserted-by":"publisher","unstructured":"Philip H, Li et al. Ruby Pawankar,Bernard Yu-Hor Thong,Jie Shen Fok,Hiroshi Chantaphakul,Michihiro Hide,. Epidemiology, Management, and Treatment Access of Hereditary Angioedema in the Asia Pacific Region: Outcomes From an International Survey. J Allergy Clin Immunol Pract. 2023;11(4):1253\u20131260. https:\/\/doi.org\/10.1016\/j.jaip.2022.12.021","DOI":"10.1016\/j.jaip.2022.12.021"},{"key":"3988_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","volume":"15","author":"S Betschel","year":"2019","unstructured":"Betschel S, Badiou J, Binkley K, BoriciMazi R, H\u00e9bert J, Kanani A, et al. The international\/canadian hereditary angioedema Guideline[J]. Allergy Asthma Clin Immunol. 2019;15:72. https:\/\/doi.org\/10.1186\/s13223-019-0376-8.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3988_CR6","doi-asserted-by":"publisher","unstructured":"Bruce LZ,Konrad Bork,Laurence Bouillet,Sandra, Christiansen,Henriette C, Farkas,Anastasios E, Germenis et al. Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment. Clin Rev Allergy Immunol. 2025;68(1):24. https:\/\/doi.org\/10.1007\/s12016-025-09027-4","DOI":"10.1007\/s12016-025-09027-4"},{"issue":"4","key":"3988_CR7","doi-asserted-by":"publisher","first-page":"100166","DOI":"10.1016\/j.jacig.2023.100166","volume":"2","author":"JCY Wong","year":"2023","unstructured":"Wong JCY, Chiang V, Lam DLY, Lee E, Lam K, Au EYL, et al. Long-term prophylaxis for hereditary angioedema: initial experiences with Garadacimab and lanadelumab. J Allergy Clin Immunol Glob. 2023;2(4):100166. https:\/\/doi.org\/10.1016\/j.jacig.2023.100166.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"3","key":"3988_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000541242","volume":"186","author":"YRDBYY Wo","year":"2025","unstructured":"Wo YRDBYY, Li WB, Li T, et al. Initial experience of Long-Term prophylaxis with lanadelumab for hereditary angioedema in china: A clinical observation study on six patients. Int Arch Allergy Immunol. 2025;186(3):221\u201331. https:\/\/doi.org\/10.1159\/000541242.","journal-title":"Int Arch Allergy Immunol"},{"key":"3988_CR9","doi-asserted-by":"publisher","unstructured":"Marcus M et al. Markus Magerl,Stephen Betschel,Werner Aberer,Ignacio J Ansotegui,Emel Ayg\u00f6ren-P\u00fcrs\u00fcn,. The international WAO\/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. Allergy. 2022;77(7):1961\u20131990. https:\/\/doi.org\/10.1111\/all.15214","DOI":"10.1111\/all.15214"},{"issue":"5","key":"3988_CR10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/all.14144","volume":"75","author":"K Weller","year":"2020","unstructured":"Weller K, Donoso T, Magerl M, Aygoren-Pursun E, Staubach P, Martinez-Saguer I, et al. Development of the angioedema control Test-A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy. 2020;75(5):1165\u201377. https:\/\/doi.org\/10.1111\/all.14144.","journal-title":"Allergy"},{"key":"3988_CR11","doi-asserted-by":"publisher","unstructured":"Hugo WF, Mak,Jane CY, Wong,Sophia WM, So,Dorothy LY, Lam,Karsten, Weller,Marcus, Maurer et al. Validation and correlations of the Angioedema Activity Score (AAS), Angioedema Quality of Life (AE-QoL) questionnaire, and Angioedema Control Test (AECT) in Chinese patients with angioedema. J Allergy Clin Immunol Glob. 2024;3(4):100295. https:\/\/doi.org\/10.1016\/j.jacig.2024.100295","DOI":"10.1016\/j.jacig.2024.100295"},{"issue":"6","key":"3988_CR12","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.jaip.2020.02.038","volume":"8","author":"K Weller","year":"2020","unstructured":"Weller K, Donoso T, Magerl M, Aygoren-Pursun E, Staubach P, Martinez-Saguer I, et al. Validation of the angioedema control test (AECT)-A Patient-Reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract. 2020;8(6):2050\u2013e20574. https:\/\/doi.org\/10.1016\/j.jaip.2020.02.038.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"3988_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/all.12007","volume":"67","author":"K Weller","year":"2012","unstructured":"Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67(10):1289\u201398. https:\/\/doi.org\/10.1111\/all.12007.","journal-title":"Allergy"},{"issue":"8","key":"3988_CR14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/all.12900","volume":"71","author":"K Weller","year":"2016","unstructured":"Weller K, Magerl M, Peveling-Oberhag A, Martus P, Staubach P, Maurer M. The angioedema quality of life questionnaire (AE-QoL)\u2014assessment of sensitivity to change and minimal clinically important difference. Allergy. 2016;71(8):1203\u20139. https:\/\/doi.org\/10.1111\/all.12900.","journal-title":"Allergy"},{"issue":"2","key":"3988_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s0022-3999(01)00296-3","volume":"52","author":"A Ingvar Bjelland,Alv","year":"2002","unstructured":"Ingvar Bjelland,Alv A, Dahl, Tone Tangen Haug,Dag Neckelmann. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res. 2002;52(2):69\u201377. https:\/\/doi.org\/10.1016\/s0022-3999(01)00296-3.","journal-title":"J Psychosom Res"},{"issue":"4","key":"3988_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1684\/ejd.2013.2105","volume":"23","author":"Y-Y Xu","year":"2013","unstructured":"Xu Y-Y, Jiang Y, Zhi Y-X, Yin J, Wang L-L, Wen L-P, et al. Clinical features of hereditary angioedema in Chinese patients: new findings and differences from other populations. Eur J Dermatol. 2013;23(4):500\u20134. https:\/\/doi.org\/10.1684\/ejd.2013.2105.","journal-title":"Eur J Dermatol"},{"key":"3988_CR17","doi-asserted-by":"publisher","unstructured":"Chawla,Elaine AKJ, Au YL et al. Screening for type II hereditary angioedema-thepoor man\u2019s c1-inhibitor function. J Allergy Clin Immunol Glob. 2023;3(1):100179. https:\/\/doi.org\/10.1016\/j.jacig.2023.100179","DOI":"10.1016\/j.jacig.2023.100179"},{"issue":"2","key":"3988_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12016-016-8561-8","volume":"51","author":"BL Zuraw","year":"2016","unstructured":"Zuraw BL, Christiansen SC. HAE pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol. 2016;51(2):216\u201329. https:\/\/doi.org\/10.1007\/s12016-016-8561-8.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"3988_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/cea.13506","volume":"49","author":"MDA Maurizio Margaglione","year":"2019","unstructured":"Maurizio Margaglione MDA, Santocroce R, Angela Bruna Maffione. Hereditary angioedema: looking for Bradykinin production and triggers of vascular permeability. Clin Exp Allergy. 2019;49(11):1395\u2013402. https:\/\/doi.org\/10.1111\/cea.13506.","journal-title":"Clin Exp Allergy"},{"key":"3988_CR20","doi-asserted-by":"publisher","unstructured":"Magerl,Hilary AZM. J Longhurst,Werner Aberer,Teresa Caballero,Laurence Bouillet, Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey. Clin Transl Allergy. 2018 Oct 12:8:42. https:\/\/doi.org\/10.1186\/s13601-018-0229-4","DOI":"10.1186\/s13601-018-0229-4"},{"issue":"1","key":"3988_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5114\/ada.2024.144488","volume":"42","author":"Makbule Seda Bayrak Durmaz,Nurgul Sevimli","year":"2025","unstructured":"Makbule Seda Bayrak Durmaz,Nurgul Sevimli. Attack frequency and associated factors in hereditary angioedema patients: a single-centre experience. Postepy Dermatol Alergol. 2025;42(1):75\u201382. https:\/\/doi.org\/10.5114\/ada.2024.144488.","journal-title":"Postepy Dermatol Alergol"},{"key":"3988_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/0091-6749(86)90424-0","volume":"77","author":"CM Brickman","year":"1986","unstructured":"Brickman CM, Tsokos GC, Balow JE, Lawley TJ, Santaella M, Hammer CH, et al. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol. 1986;77:749\u201357.","journal-title":"J Allergy Clin Immunol"},{"key":"3988_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/0091-6749(86)90425-2","volume":"77","author":"CM Brickman","year":"1986","unstructured":"Brickman CM, Tsokos GC, Chused TM, Balow JE, Lawley TJ, Santaella M, et al. Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. J Allergy Clin Immunol. 1986;77:758\u201367.","journal-title":"J Allergy Clin Immunol"},{"key":"3988_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clim.2011.05.004","volume":"141","author":"H Farkas","year":"2011","unstructured":"Farkas H, Csuka D, G\u00e1cs J, Czaller I, Zotter Z, F\u00fcst G, et al. Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency. Clin Immunol. 2011;141:58\u201366.","journal-title":"Clin Immunol"},{"key":"3988_CR25","unstructured":"Stepaniuk P, Kanani A. Malignancy and immune disorders in patients with hereditary angioedema. Allergy, Asthma & Clinical Immunology"},{"issue":"3","key":"3988_CR26","doi-asserted-by":"publisher","first-page":"e12135","DOI":"10.1002\/clt2.12135","volume":"12","author":"Linda Sundler Bj\u00f6rkman","year":"2022","unstructured":"Linda Sundler Bj\u00f6rkman. Barbro persson,david aronsson,lillemor skattum,patrik nordenfelt,arne egesten. Comorbidities in hereditary angioedema-A population-based cohort study. Clin Transl Allergy. 2022;12(3):e12135. https:\/\/doi.org\/10.1002\/clt2.12135.","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"3988_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s13023-022-02536-x","volume":"17","author":"GHZHLH Yinshi","year":"2022","unstructured":"Yinshi GHZHLH, Wang,Herberto J, Chong-Neto,Solange OR, Valle, et al. Long-term prophylaxis with androgens in the management of hereditary angioedema (HAE) in emerging countries. Orphanet J Rare Dis. 2022;17(1):399. https:\/\/doi.org\/10.1186\/s13023-022-02536-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"34","key":"3988_CR28","doi-asserted-by":"publisher","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","volume":"289","author":"A Jon","year":"2014","unstructured":"Jon A, Kenniston RR, Faucette D, Martik SR, Comeau, Allison P, Lindberg, Kris J, Kopacz, et al. Inhibition of plasma Kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014;289(34):23596\u2013608. https:\/\/doi.org\/10.1074\/jbc.M114.569061.","journal-title":"J Biol Chem"},{"key":"3988_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1605767","volume":"376","author":"A Banerji","year":"2017","unstructured":"Banerji A, Busse P, Shennak M, Lumry W, DavisLorton M, Wedner HJ, et al. Inhibiting plasma Kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017;376:717\u201328.","journal-title":"N Engl J Med"},{"issue":"20","key":"3988_CR30","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108\u201321. https:\/\/doi.org\/10.1001\/jama.2018.16773.","journal-title":"JAMA"},{"issue":"1","key":"3988_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132\u2013e1503. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.046.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3988_CR32","doi-asserted-by":"publisher","unstructured":"Xu Y, Cheng SLXWWCL,Yinshi, Guo et al. Chinese expert consensus on the diagnosis and treatment of hereditary angioedema (2024 edition). Int Arch Allergy Immunol. 2025 Apr 10:1\u201313. https:\/\/doi.org\/10.1159\/000545808","DOI":"10.1159\/000545808"},{"key":"3988_CR33","doi-asserted-by":"publisher","unstructured":"Li PH, Wang,Jane J-XHC-T, Wong,Hao CY, Chen,Bao, Chai et al. Hereditary Angioedema (HAE) in China Advancing Awareness, Access, Advocacy and Alliances From the Greater Bay Area to the Global HAE Community. Clin Exp Allergy. 2025 Mar 4. https:\/\/doi.org\/10.1111\/cea.70014","DOI":"10.1111\/cea.70014"},{"key":"3988_CR34","doi-asserted-by":"publisher","unstructured":"Thomas Buttgereit CV, Ayala S, Aykanat K, Weller A, Gutsche M, Maurer et al. The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center. Front Immunol 2024 May 10:151405317. https:\/\/doi.org\/10.3389\/fimmu.2024.1405317","DOI":"10.3389\/fimmu.2024.1405317"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03988-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T06:41:29Z","timestamp":1757400089000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03988-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3988"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03988-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6057336\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Ethics Committee of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, approval number LY2024-243B","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"441"}}